Drug Trial Radar · NCT07181109
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
11,000
Planned (sponsor's estimate)
Start
Sep 6, 2025
Primary completion
Sep 23, 2030
Study completion Sep 23, 2030
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- Collaborators
- Hoffmann-La Roche
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.
Conditions
- High Risk Cardiovascular Disease
- Hypertension
- High Cardiovascular Risk
Interventions
ZilebesiranDrug
Zilebesiran will be administered SC
PlaceboDrug
Placebo will be administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Occurrence of a Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Heart Failure (HF) Event (Hospitalization for HF or Urgent HF Visit)Time frame: Up to approximately 5 years
Locations
1,226 sites in 35 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Birmingham, Alabama · Recruiting
Clinical Trial Site
Birmingham, Alabama · Recruiting
Clinical Trial Site
Fairhope, Alabama · Recruiting
Clinical Trial Site
Foley, Alabama · Recruiting
Clinical Trial Site
Huntsville, Alabama · Recruiting
Clinical Trial Site
Huntsville, Alabama · Recruiting
Clinical Trial Site
Sheffield, Alabama · Recruiting
Clinical Trial Site
Chandler, Arizona · Recruiting
Clinical Trial Site
Gilbert, Arizona · Recruiting
Clinical Trial Site
Glendale, Arizona · Completed
Clinical Trial Site
Mesa, Arizona · Recruiting
Clinical Trial Site
Phoenix, Arizona · Recruiting
Clinical Trial Site
Phoenix, Arizona · Recruiting
Clinical Trial Site
Sun City, Arizona · Recruiting
Clinical Trial Site
Sun City West, Arizona · Recruiting
Clinical Trial Site
Tempe, Arizona · Recruiting
Clinical Trial Site
Tucson, Arizona · Recruiting
Clinical Trial Site
Tucson, Arizona · Recruiting
Clinical Trial Site
Yuma, Arizona · Recruiting
Clinical Trial Site
Little Rock, Arkansas · Recruiting
Clinical Trial Site
Little Rock, Arkansas · Recruiting
Clinical Trial Site
Beverly Hills, California · Recruiting
Clinical Trial Site
Chula Vista, California · Recruiting
Clinical Trial Site
Covina, California · Recruiting
Clinical Trial Site
Escondido, California · Recruiting
Clinical Trial Site
Glendale, California · Recruiting
Clinical Trial Site
Huntington Beach, California · Recruiting
Clinical Trial Site
La Jolla, California · Recruiting
Clinical Trial Site
Lancaster, California · Recruiting
Clinical Trial Site
Long Beach, California · Recruiting
Clinical Trial Site
Lynwood, California · Recruiting
Clinical Trial Site
Newhall, California · Recruiting
Clinical Trial Site
Northridge, California · Recruiting
Clinical Trial Site
Pasadena, California · Recruiting
Clinical Trial Site
San Diego, California · Recruiting
Clinical Trial Site
San Dimas, California · Recruiting
Clinical Trial Site
San Ramon, California · Recruiting
Clinical Trial Site
Stockton, California · Recruiting
Clinical Trial Site
Tarzana, California · Recruiting
Clinical Trial Site
Toluca Lake, California · Recruiting
Showing 40 of 1,226 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.